It has been established that IL-1 and NLRP-3 inflammasomes are key drivers of anticancer drug-mediated cardiac dysfunctions, including heart failure, a decrease in the left ventricular ejection fraction, EF and cardiac fibrosis [76,77]. Here, NLRP3 is linked to heart failure.